Format

Send to

Choose Destination
Int J Pharm. 2017 Nov 5;532(2):757-768. doi: 10.1016/j.ijpharm.2017.04.064. Epub 2017 Apr 27.

Development and evaluation of injectable nanosized drug delivery systems for apigenin.

Author information

1
Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium; MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France. Electronic address: reatul.karim@ulg.ac.be.
2
Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium.
3
Namur Nanosafety Centre, NARILIS, Department of Pharmacy, University of Namur, Namur, Belgium.
4
Center for Education and Research on Macromolecules (CERM), University of Liege, UR-CESAM, Liege, Belgium.
5
MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France.
6
Université Côte d'Azur, Centre Commun de Microscopie Appliquée, Nice, France.

Abstract

The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and compare their characteristics to identify the nanovector(s) that can deliver the largest quantity of AG while being biocompatible. Two liposomes with different surface characteristics (cationic and anionic), a LNC and a PNC were prepared. A novel tocopherol modified poly(ethylene glycol)-b-polyphosphate block-copolymer was used for the first time for the PNC preparation. The NDDSs were compared by their physicochemical characteristics, AG release, storage stability, stability in serum, complement consumption and toxicity against a human macrovascular endothelial cell line (EAhy926). The diameter and surface charge of the NDDSs were comparable with previously reported injectable nanocarriers. The NDDSs showed good encapsulation efficiency and drug loading. Moreover, the NDDSs were stable during storage and in fetal bovine serum for extended periods, showed low complement consumption and were non-toxic to EAhy926 cells up to high concentrations. Therefore, they can be considered as potential injectable nanocarriers of AG. Due to less pronounced burst effect and extended release characteristics, the nanocapsules could be favorable approaches for achieving prolonged pharmacological activity of AG using injectable NDDS.

KEYWORDS:

Apigenin; Injectable nanocarrier; Lipid nanocapsule; Liposome; Polymeric nanocapsule

PMID:
28456651
DOI:
10.1016/j.ijpharm.2017.04.064
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center